Tus-Pharmaceutical Group Co., Ltd. Logo

Tus-Pharmaceutical Group Co., Ltd.

000590.SZ

(1.2)
Stock Price

8,26 CNY

-0.52% ROA

-0.64% ROE

-356.27x PER

Market Cap.

1.614.034.540,00 CNY

13.72% DER

0% Yield

-1.27% NPM

Tus-Pharmaceutical Group Co., Ltd. Stock Analysis

Tus-Pharmaceutical Group Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Tus-Pharmaceutical Group Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (15%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE falls within an average range (1.26%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (1.07%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 Buffet Intrinsic Value

The company's stock seems undervalued (172) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.14x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Tus-Pharmaceutical Group Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Tus-Pharmaceutical Group Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Tus-Pharmaceutical Group Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Tus-Pharmaceutical Group Co., Ltd. Revenue
Year Revenue Growth
1992 32.345.500
1993 62.679.500 48.4%
1994 74.618.700 16%
1995 93.846.682 20.49%
1996 69.055.926 -35.9%
1997 133.901.173 48.43%
1998 198.325.972 32.48%
1999 219.627.365 9.7%
2000 283.561.384 22.55%
2001 245.678.437 -15.42%
2002 296.606.103 17.17%
2003 238.165.543 -24.54%
2004 267.089.665 10.83%
2005 271.110.822 1.48%
2006 286.824.832 5.48%
2007 207.905.036 -37.96%
2008 236.573.558 12.12%
2009 274.089.961 13.69%
2010 311.624.913 12.04%
2011 343.508.517 9.28%
2012 363.420.444 5.48%
2013 256.000.679 -41.96%
2014 203.122.000 -26.03%
2015 294.719.555 31.08%
2016 317.410.504 7.15%
2017 343.539.198 7.61%
2018 185.811.015 -84.89%
2019 315.034.457 41.02%
2020 275.090.121 -14.52%
2021 300.774.612 8.54%
2022 350.528.110 14.19%
2023 338.316.540 -3.61%
2023 395.923.041 14.55%
2024 278.239.264 -42.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Tus-Pharmaceutical Group Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1.916.221 100%
2011 3.526.567 45.66%
2012 2.296.740 -53.55%
2013 2.608.432 11.95%
2014 4.365.981 40.26%
2015 4.814.649 9.32%
2016 5.951.210 19.1%
2017 5.538.020 -7.46%
2018 7.484.586 26.01%
2019 9.459.816 20.88%
2020 9.594.178 1.4%
2021 8.289.522 -15.74%
2022 13.103.555 36.74%
2023 12.638.761 -3.68%
2023 12.038.256 -4.99%
2024 16.646.036 27.68%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Tus-Pharmaceutical Group Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 2.706.700
1993 5.253.300 48.48%
1994 4.639.100 -13.24%
1995 4.973.764 6.73%
1996 4.156.244 -19.67%
1997 9.382.689 55.7%
1998 20.013.762 53.12%
1999 28.249.970 29.15%
2000 48.152.810 41.33%
2001 76.309.482 36.9%
2002 58.121.515 -31.29%
2003 61.480.168 5.46%
2004 61.337.379 -0.23%
2005 59.003.849 -3.95%
2006 62.058.483 4.92%
2007 38.755.579 -60.13%
2008 46.676.677 16.97%
2009 52.817.546 11.63%
2010 16.312.449 -223.79%
2011 16.230.746 -0.5%
2012 22.802.655 28.82%
2013 31.879.897 28.47%
2014 16.416.391 -94.2%
2015 12.051.383 -36.22%
2016 9.973.262 -20.84%
2017 13.534.787 26.31%
2018 8.766.469 -54.39%
2019 8.985.340 2.44%
2020 8.477.517 -5.99%
2021 9.146.571 7.31%
2022 12.052.034 24.11%
2023 203.625.180 94.08%
2023 12.328.882 -1551.61%
2024 -57.259.458 121.53%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Tus-Pharmaceutical Group Co., Ltd. EBITDA
Year EBITDA Growth
1992 3.960.500
1993 10.877.500 63.59%
1994 17.586.100 38.15%
1995 21.292.979 17.41%
1996 15.040.266 -41.57%
1997 29.594.341 49.18%
1998 39.576.271 25.22%
1999 33.096.251 -19.58%
2000 54.112.357 38.84%
2001 -39.339.778 237.55%
2002 33.057.388 219%
2003 9.461.314 -249.4%
2004 45.471.302 79.19%
2005 45.498.071 0.06%
2006 47.007.544 3.21%
2007 64.933.981 27.61%
2008 63.071.407 -2.95%
2009 42.363.554 -48.88%
2010 83.817.794 49.46%
2011 130.468.663 35.76%
2012 187.234.170 30.32%
2013 -78.052.362 339.88%
2014 -55.903.251 -39.62%
2015 56.062.412 199.72%
2016 90.674.492 38.17%
2017 38.922.219 -132.96%
2018 -10.856.546 458.51%
2019 50.518.958 121.49%
2020 43.731.879 -15.52%
2021 62.996.808 30.58%
2022 47.176.934 -33.53%
2023 5.217.544 -804.2%
2023 34.357.090 84.81%
2024 -47.731.292 171.98%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Tus-Pharmaceutical Group Co., Ltd. Gross Profit
Year Gross Profit Growth
1992 11.006.600
1993 25.100.300 56.15%
1994 31.608.900 20.59%
1995 39.795.011 20.57%
1996 32.678.446 -21.78%
1997 59.585.813 45.16%
1998 84.732.341 29.68%
1999 111.798.325 24.21%
2000 143.832.288 22.27%
2001 94.411.946 -52.35%
2002 108.772.461 13.2%
2003 97.714.731 -11.32%
2004 129.221.905 24.38%
2005 131.812.192 1.97%
2006 104.886.759 -25.67%
2007 106.754.023 1.75%
2008 120.683.144 11.54%
2009 143.077.954 15.65%
2010 177.912.633 19.58%
2011 193.262.175 7.94%
2012 185.468.622 -4.2%
2013 130.522.356 -42.1%
2014 104.892.929 -24.43%
2015 162.760.538 35.55%
2016 166.848.792 2.45%
2017 192.802.251 13.46%
2018 87.756.616 -119.7%
2019 167.664.094 47.66%
2020 153.279.207 -9.38%
2021 166.259.591 7.81%
2022 179.201.595 7.22%
2023 170.466.225 -5.12%
2023 189.871.436 10.22%
2024 120.952.652 -56.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Tus-Pharmaceutical Group Co., Ltd. Net Profit
Year Net Profit Growth
1992 2.602.800
1993 8.062.200 67.72%
1994 15.000.400 46.25%
1995 13.450.510 -11.52%
1996 15.628.383 13.94%
1997 24.133.136 35.24%
1998 27.865.405 13.39%
1999 12.463.674 -123.57%
2000 30.329.956 58.91%
2001 -59.670.419 150.83%
2002 4.098.396 1555.95%
2003 -26.236.801 115.62%
2004 5.426.330 583.51%
2005 4.290.012 -26.49%
2006 2.894.261 -48.22%
2007 20.517.350 85.89%
2008 20.374.461 -0.7%
2009 -88.167.117 123.11%
2010 47.153.713 286.98%
2011 72.134.381 34.63%
2012 137.606.335 47.58%
2013 -164.450.534 183.68%
2014 -85.770.538 -91.73%
2015 22.372.282 483.38%
2016 55.175.215 59.45%
2017 19.173.756 -187.76%
2018 -38.180.406 150.22%
2019 42.442.308 189.96%
2020 22.722.397 -86.79%
2021 35.438.603 35.88%
2022 18.109.854 -95.69%
2023 190.436 -9409.73%
2023 25.246.778 99.25%
2024 -60.441.163 141.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Tus-Pharmaceutical Group Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1 0%
2013 -1 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Tus-Pharmaceutical Group Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -5.430.249
1999 -25.440.856 78.66%
2000 -20.450.246 -24.4%
2001 -94.445.769 78.35%
2002 26.284.973 459.31%
2003 -35.564.425 173.91%
2004 41.168.160 186.39%
2005 40.485.572 -1.69%
2006 -24.433.241 265.7%
2007 65.898.774 137.08%
2008 20.890.995 -215.44%
2009 15.269.798 -36.81%
2010 60.117.825 74.6%
2011 8.182.490 -634.71%
2012 4.466.800 -83.18%
2013 -10.909.062 140.95%
2014 -138.303.062 92.11%
2015 -90.696.727 -52.49%
2016 -49.147.474 -84.54%
2017 -113.020.419 56.51%
2018 -21.931.538 -415.33%
2019 -6.633.045 -230.64%
2020 17.575.069 137.74%
2021 -679.274 2687.34%
2022 35.789.237 101.9%
2023 -50.436.998 170.96%
2023 -6.707.546 -651.94%
2024 50.447.328 113.3%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Tus-Pharmaceutical Group Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 3.888.865
1999 -10.345.766 137.59%
2000 8.232.240 225.67%
2001 -50.999.314 116.14%
2002 94.297.140 154.08%
2003 -24.429.624 486%
2004 48.459.527 150.41%
2005 55.959.294 13.4%
2006 -23.332.859 339.83%
2007 68.039.949 134.29%
2008 34.885.632 -95.04%
2009 34.144.677 -2.17%
2010 84.978.226 59.82%
2011 30.866.206 -175.31%
2012 19.746.060 -56.32%
2013 4.122.159 -379.02%
2014 -50.908.087 108.1%
2015 -60.559.967 15.94%
2016 -32.513.859 -86.26%
2017 -89.144.168 63.53%
2018 654.237 13725.67%
2019 29.208.436 97.76%
2020 51.480.579 43.26%
2021 25.196.296 -104.32%
2022 54.473.687 53.75%
2023 -28.394.717 291.84%
2023 0 0%
2024 54.404.492 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Tus-Pharmaceutical Group Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 9.319.114
1999 15.095.090 38.26%
2000 28.682.486 47.37%
2001 43.446.455 33.98%
2002 68.012.167 36.12%
2003 11.134.801 -510.81%
2004 7.291.366 -52.71%
2005 15.473.722 52.88%
2006 1.100.382 -1306.21%
2007 2.141.174 48.61%
2008 13.994.637 84.7%
2009 18.874.878 25.86%
2010 24.860.400 24.08%
2011 22.683.716 -9.6%
2012 15.279.260 -48.46%
2013 15.031.221 -1.65%
2014 87.394.975 82.8%
2015 30.136.760 -189.99%
2016 16.633.615 -81.18%
2017 23.876.252 30.33%
2018 22.585.775 -5.71%
2019 35.841.481 36.98%
2020 33.905.509 -5.71%
2021 25.875.570 -31.03%
2022 18.684.450 -38.49%
2023 22.042.281 15.23%
2023 6.707.546 -228.62%
2024 3.957.164 -69.5%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Tus-Pharmaceutical Group Co., Ltd. Equity
Year Equity Growth
1995 65.318.521
1996 141.912.341 53.97%
1997 240.919.016 41.1%
1998 268.784.421 10.37%
1999 347.797.686 22.72%
2000 380.017.964 8.48%
2001 278.650.261 -36.38%
2002 280.905.553 0.8%
2003 259.160.611 -8.39%
2004 267.568.195 3.14%
2005 268.539.048 0.36%
2006 271.260.491 1%
2007 307.216.082 11.7%
2008 322.777.599 4.82%
2009 230.751.876 -39.88%
2010 289.339.286 20.25%
2011 361.291.417 19.92%
2012 478.581.409 24.51%
2013 269.510.747 -77.57%
2014 184.106.375 -46.39%
2015 205.794.093 10.54%
2016 263.955.888 22.03%
2017 583.331.152 54.75%
2018 579.718.759 -0.62%
2019 622.161.068 6.82%
2020 644.883.465 3.52%
2021 682.321.335 5.49%
2022 702.493.870 2.87%
2023 708.887.622 0.9%
2023 728.203.004 2.65%
2024 705.276.567 -3.25%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Tus-Pharmaceutical Group Co., Ltd. Assets
Year Assets Growth
1995 141.056.240
1996 187.456.821 24.75%
1997 373.150.802 49.76%
1998 404.346.957 7.72%
1999 596.855.823 32.25%
2000 636.255.452 6.19%
2001 695.049.908 8.46%
2002 724.861.291 4.11%
2003 685.159.664 -5.79%
2004 676.627.485 -1.26%
2005 664.583.510 -1.81%
2006 545.358.971 -21.86%
2007 548.583.251 0.59%
2008 571.308.293 3.98%
2009 516.334.757 -10.65%
2010 568.726.301 9.21%
2011 602.453.690 5.6%
2012 704.017.626 14.43%
2013 552.561.938 -27.41%
2014 586.820.654 5.84%
2015 587.434.583 0.1%
2016 630.679.185 6.86%
2017 873.736.015 27.82%
2018 816.598.767 -7%
2019 846.744.431 3.56%
2020 892.157.636 5.09%
2021 967.825.750 7.82%
2022 1.166.753.854 17.05%
2023 1.117.443.923 -4.41%
2023 1.151.120.901 2.93%
2024 1.128.556.299 -2%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Tus-Pharmaceutical Group Co., Ltd. Liabilities
Year Liabilities Growth
1995 75.737.718
1996 45.544.479 -66.29%
1997 132.231.786 65.56%
1998 135.562.535 2.46%
1999 249.058.136 45.57%
2000 256.237.487 2.8%
2001 416.399.645 38.46%
2002 443.955.737 6.21%
2003 425.999.052 -4.22%
2004 409.059.288 -4.14%
2005 396.044.461 -3.29%
2006 274.098.480 -44.49%
2007 241.367.168 -13.56%
2008 248.530.693 2.88%
2009 285.112.176 12.83%
2010 289.845.585 1.63%
2011 251.620.842 -15.19%
2012 225.436.216 -11.62%
2013 283.051.191 20.35%
2014 402.714.279 29.71%
2015 381.640.490 -5.52%
2016 366.723.296 -4.07%
2017 290.404.862 -26.28%
2018 236.880.008 -22.6%
2019 224.583.363 -5.48%
2020 247.274.170 9.18%
2021 285.504.415 13.39%
2022 464.259.983 38.5%
2023 408.556.301 -13.63%
2023 380.475.355 -7.38%
2024 423.279.731 10.11%

Tus-Pharmaceutical Group Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.49
Net Income per Share
-0.02
Price to Earning Ratio
-356.27x
Price To Sales Ratio
4.52x
POCF Ratio
69.27
PFCF Ratio
727.69
Price to Book Ratio
2.3
EV to Sales
4.28
EV Over EBITDA
-87.22
EV to Operating CashFlow
65.64
EV to FreeCashFlow
689.54
Earnings Yield
-0
FreeCashFlow Yield
0
Market Cap
1,61 Bil.
Enterprise Value
1,53 Bil.
Graham Number
1.12
Graham NetNet
-0.1

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
-5.14
ROE
-0.01
Return On Assets
-0
Return On Capital Employed
-0.03
Net Income per EBT
-304.63
EBT Per Ebit
-0
Ebit per Revenue
-0.08
Effective Tax Rate
326.67

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.48
Operating Profit Margin
-0.08
Pretax Profit Margin
0
Net Profit Margin
-0.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.87
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.1
Free CashFlow per Share
0.01
Capex to Operating CashFlow
0.9
Capex to Revenue
0.06
Capex to Depreciation
2.72
Return on Invested Capital
11.59
Return on Tangible Assets
-0.01
Days Sales Outstanding
169.14
Days Payables Outstanding
166.2
Days of Inventory on Hand
291.48
Receivables Turnover
2.16
Payables Turnover
2.2
Inventory Turnover
1.25
Capex per Share
0.09

Balance Sheet

Cash per Share
0,84
Book Value per Share
2,95
Tangible Book Value per Share
1.85
Shareholders Equity per Share
2.92
Interest Debt per Share
0.42
Debt to Equity
0.14
Debt to Assets
0.09
Net Debt to EBITDA
4.83
Current Ratio
2.09
Tangible Asset Value
0,44 Bil.
Net Current Asset Value
0,09 Bil.
Invested Capital
828921078
Working Capital
0,27 Bil.
Intangibles to Total Assets
0.23
Average Receivables
0,20 Bil.
Average Payables
0,07 Bil.
Average Inventory
148735337
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Tus-Pharmaceutical Group Co., Ltd. Dividends
Year Dividends Growth
1996 0
1997 0 0%
2000 0 0%
2012 0 0%
2013 0 0%

Tus-Pharmaceutical Group Co., Ltd. Profile

About Tus-Pharmaceutical Group Co., Ltd.

Tus-Pharmaceutical Group Co., Ltd. manufactures and sells traditional Chinese medicine and western medicine products. The company was formerly known as Tus-Guhan Group Corp.,Ltd. Tus-Pharmaceutical Group Co., Ltd. was founded in 1956 and is based in Hengyang, China.

CEO
Ms. Ting Tang
Employee
1.237
Address
No. 33, Yangliu Road
Hengyang, 421001

Tus-Pharmaceutical Group Co., Ltd. Executives & BODs

Tus-Pharmaceutical Group Co., Ltd. Executives & BODs
# Name Age
1 Ms. Ting Tang
Vice President, Chief Financial Officer & Non Independent Director
70
2 Mr. Dingxing Cao
Vice President & Board Secretary
70
3 Mr. Jun Cai
Vice President
70
4 Mr. Xue Feng
President & Non Independent Director
70

Tus-Pharmaceutical Group Co., Ltd. Competitors